Evidence map›Paper›PMID 38232106›Full record

ArticlePloS one2024

B memory cell responses to LPS, IVP and IpaB antigen after oral vaccination with Shigella sonnei vaccine candidates WRSs2 and WRSs3.

Malabi M Venkatesan, Shoshana Barnoy, Robert Frenck, Monica McNeal, Shahida Baqar

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Malabi M VenkatesanUS Army Bacterial Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.ORCID 0000-0001-7790-1286
Shoshana BarnoyUS Army Bacterial Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Robert FrenckDivision of Infectious Diseases, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America.ORCID 0000-0002-2336-526X
Monica McNealDivision of Infectious Diseases, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America.ORCID 0000-0002-3784-9062
Shahida BaqarDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Cincinnati Children's Hospital Medical Center · USWalter Reed Army Institute of Research · USNational Institutes of Health · US

Funding

NIAID NIH HHS HHSN272200800006CNIAID NIH HHS HHSN272200800013C
6 · The paper itself

Abstract

B memory (BM) cell responses were evaluated using peripheral blood mononuclear cells that were collected and cryopreserved during a Phase 1 trial of two live Shigella sonnei vaccine candidates WRSs2 and WRSs3. An ELISpot assay was used to measure IgG+ and IgA+ BM cell responses against S. sonnei LPS, IVP and IpaB antigens. Analysis of BM cell responses at baseline, and on days 28 and 56 post vaccination indicate that after a single oral dose of WRSs2 and WRSs3, both groups of vaccinees induced IgG+ and IgA+ BM cell responses that were variable in magnitude among subjects and reached significance to IVP and IpaB at several doses. The responses generally peaked at d28 after vaccination. The baseline as well as post-vaccination levels of IgA+ BM cells were relatively higher than IgG+ BM cells, but the maximum fold-increase at d28/d56 over baseline was greater for IgG+ than IgA+ BM cell responses. Furthermore, at the three highest vaccine doses, >60-90% of subjects were considered responders indicating a ≥2-fold higher IgG+ BM cell responses to IVP and IpaB post vaccination, while fewer subjects indicated the same level of response to LPS.

Indexed as

Shigella sonneiShigella VaccinesAntibodies, BacterialAntigensBacterial ProteinsClinical Trials, Phase I as TopicHumansImmunoglobulin AImmunoglobulin GLeukocytes, MononuclearLipopolysaccharidesVaccinationVaccines, AttenuatedAntibodies, BacterialAntigensBacterial ProteinsImmunoglobulin AImmunoglobulin GLipopolysaccharidesShigella VaccinesVaccines, Attenuated

Identifiers

PMID38232106
PMCPMC10793881
OpenAlexW4390939307

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.